Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 7/20 | 0.69 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ABL2 | P42684 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27604456 | 0.83 | TRPA1 (0.71) | FADS1GRM4FLT3TRPA1SMN1; SMN2 | |
| SCHEMBL802142 | 0.82 | GRM4 (0.66) | FADS1GRM4FLT3MAP4K1TRPA1 | |
| SCHEMBL29882003 | 0.82 | TRPA1 (0.75) | FADS1GRM4FLT3TRPA1EGFR | |
| SCHEMBL4741513 | 0.82 | TRPA1 (0.75) | FADS1GRM4FLT3TRPA1EGFR | |
| SCHEMBL4785847 | 0.82 | FADS1 (1.00) | FADS1GRM4TRPA1EGFRHTT | |
| SCHEMBL4783454 | 0.82 | FADS1 (1.00) | FADS1GRM4TRPA1EGFRSMN1; SMN2 | |
| SCHEMBL22328228 | 0.81 | GRM4 (0.67) | FADS1GRM4FLT3TRPA1ABCG2 | |
| SCHEMBL18415221 | 0.81 | GRM4 (0.67) | FADS1GRM4TRPA1EGFRADRA2A | |
| SCHEMBL627286 | 0.80 | FADS1 (0.57) | FADS1GRM4TRPA1HTTNPSR1 | |
| SCHEMBL18235582 | 0.80 | FADS1 (0.72) | FADS1GRM4TRPA1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-7691853-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-7473691-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-01-06 | — | — | US | disclosed |
| US-7390815-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070270444-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| EP-1318814-B1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | FADS1 1449/4885GRM4 4253/4885FLT3 550/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | FADS1 3442/4885GRM4 3726/4885FLT3 585/4885 |
| US-20070270444-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, CDK3, GSK3A | FADS1 1449/4885GRM4 4253/4885FLT3 550/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | FADS1 3429/4885GRM4 4741/4885FLT3 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.